AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31331617 — intervention group
Group type: EXPERIMENTAL
Intervention: LSD 26 μg
Number of subjects: 20
Study 31331617 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0 μg)
Number of subjects: 20
Study 28936608 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0‐msec pulse width
Number of subjects: 20
Study 28936608 — intervention group
Group type: COMPARATOR
Intervention: 0.1‐msec pulse width
Number of subjects: 20
Study 25693988 — intervention group
Group type: EXPERIMENTAL
Intervention: Dyad practice (n = 16)
Number of subjects: 30
Study 25693988 — intervention group
Group type: COMPARATOR
Intervention: Single-student practice (n = 14)
Number of subjects: 30
Study 24666664 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl buccal tablet
Number of subjects: 130
Study 24666664 — intervention group
Group type: COMPARATOR
Intervention: Traditional short-acting opioid
Number of subjects: 130
Study 22964692 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-alcoholic steatohepatitis (NASH)
Number of subjects: 162
Study 22964692 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects (Control)
Number of subjects: 162
Study 19404938 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab plus methotrexate
Number of subjects: 794
Study 19404938 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate alone
Number of subjects: 794
Study 19404938 — intervention group
Group type: COMPARATOR
Intervention: Adalimumab alone
Number of subjects: 794
Study 17329667 — intervention group
Group type: EXPERIMENTAL
Intervention: Satellite TV training
Number of subjects: 415
Study 17329667 — intervention group
Group type: EXPERIMENTAL
Intervention: Training plus technical assistance
Number of subjects: 415
Study 17329667 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 415
Study 15220947 — intervention group
Group type: COMPARATOR
Intervention: NUTRIOSE FB 30 g/day
Number of subjects: 20
Study 15220947 — intervention group
Group type: COMPARATOR
Intervention: NUTRIOSE FB 60 g/day
Number of subjects: 20
Study 15220947 — intervention group
Group type: COMPARATOR
Intervention: NUTRIOSE FB 80 g/day
Number of subjects: 20
Study 15220947 — intervention group
Group type: COMPARATOR
Intervention: NUTRIOSE FB 10 g/day
Number of subjects: 20
Study 15220947 — intervention group
Group type: COMPARATOR
Intervention: NUTRIOSE FB 15 g/day
Number of subjects: 20
Study 15220947 — intervention group
Group type: COMPARATOR
Intervention: NUTRIOSE FB (all doses)
Number of subjects: 20
Study 15220947 — intervention group
Group type: COMPARATOR
Intervention: NUTRIOSE FB (up to 45 g/day)
Number of subjects: 20
Study 11898516 — intervention group
Group type: EXPERIMENTAL
Intervention: Various tic-suppressing treatments including hydrotherapy, behavioral treatments, pharmacotherapy, botulinum toxin, immunomodulatory therapy, and surgery; specific dosages and durations not available.
Number of subjects: 0
Study 9850434 — intervention group
Group type: EXPERIMENTAL
Intervention: Patented soft gelatine capsule with 80 mg of silybin in a 1:2 complex with phosphatidylcholine
Number of subjects: 12
Study 9850434 — intervention group
Group type: COMPARATOR
Intervention: Hard shell capsule with 80 mg of silybin in a 1:2 complex with phosphatidylcholine
Number of subjects: 12
Study 8115666 — intervention group
Group type: EXPERIMENTAL
Intervention: Piroxicam (40 mg, intramuscular injection)
Number of subjects: 0
Study 8115666 — intervention group
Group type: EXPERIMENTAL
Intervention: Lysine acetylsalicylate (500 mg, intravenous injection)
Number of subjects: 0
Study 8115666 — intervention group
Group type: COMPARATOR
Intervention: Naloxone (2 mg, intravenous injection)
Number of subjects: 0
Study 8115666 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 0
Study 30193574 — intervention group
Group type: EXPERIMENTAL
Intervention: Bonfils fiberscope
Number of subjects: 50
Study 30193574 — intervention group
Group type: COMPARATOR
Intervention: C‐MAC videolaryngoscope
Number of subjects: 50
Study 26602586 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma at the time of distraction
Number of subjects: 14
Study 26602586 — intervention group
Group type: COMPARATOR
Intervention: Distraction only (Control group)
Number of subjects: 14
Study 24265356 — intervention group
Group type: EXPERIMENTAL
Intervention: Bleach baths plus routine hygienic measures
Number of subjects: 987
Study 24265356 — intervention group
Group type: COMPARATOR
Intervention: Routine hygienic measures alone
Number of subjects: 987
Study 22898716 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive hypertrophic resistance training (RT) for 21 weeks
Number of subjects: 39
Study 19650782 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright light exposure (10,000 lux)
Number of subjects: 85
Study 19650782 — intervention group
Group type: EXPERIMENTAL
Intervention: Levothyroxine (64 nmol) and Liothyronine (16 nmol) supplement
Number of subjects: 85
Study 19650782 — intervention group
Group type: COMPARATOR
Intervention: Dim light exposure (50 lux)
Number of subjects: 85
Study 19650782 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsule
Number of subjects: 85
Study 19816018 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuroaid (MLC 601), 4 capsules 3 times a day for 4 weeks
Number of subjects: 40
Study 19816018 — intervention group
Group type: COMPARATOR
Intervention: Placebo, 4 capsules 3 times a day for 4 weeks
Number of subjects: 40
Study 19816018 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuroaid (MLC 601)
Number of subjects: 40
Study 16621658 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine agonist (DA) monotherapy
Number of subjects: 376
Study 16621658 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 376
Study 15599534 — intervention group
Group type: COMPARATOR
Intervention: Liposuction
Number of subjects: 42
Study 15599534 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2 therapy after liposuction (2 weekly applications for 10 weeks)
Number of subjects: 42
Study 15599534 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2 therapy alone (2 weekly applications for 10 weeks)
Number of subjects: 42
Study 10786744 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopexamine at 0.5 microg kg(‐1) min(‐1)
Number of subjects: 21
Study 10786744 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopexamine at 2.0 microg kg(‐1) min(‐1)
Number of subjects: 21
Study 10786744 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 10786744 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopexamine (both dosages)
Number of subjects: 21
Study 9483214 — intervention group
Group type: EXPERIMENTAL
Intervention: bcl‐2 oncoprotein
Number of subjects: 104
Study 9483214 — intervention group
Group type: EXPERIMENTAL
Intervention: L‐myc oncoprotein
Number of subjects: 104
Study 9483214 — intervention group
Group type: EXPERIMENTAL
Intervention: p53 mutated gene oncoprotein
Number of subjects: 104
Study 9483214 — intervention group
Group type: EXPERIMENTAL
Intervention: Rb gene oncoprotein
Number of subjects: 104
Study 9483214 — intervention group
Group type: EXPERIMENTAL
Intervention: IGFII
Number of subjects: 104
Study 9483214 — intervention group
Group type: EXPERIMENTAL
Intervention: IGFIBP3
Number of subjects: 104
Study 9483214 — intervention group
Group type: EXPERIMENTAL
Intervention: Ki‐67 positive cells
Number of subjects: 104
Study 9483214 — intervention group
Group type: EXPERIMENTAL
Intervention: CD44 types 5 and 6
Number of subjects: 104
Study 8311568 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine (25 mg base/kg body weight over 3 days)
Number of subjects: 166
Study 8311568 — intervention group
Group type: EXPERIMENTAL
Intervention: Amodiaquine (25 mg base/kg body weight over 3 days)
Number of subjects: 166
Study 8311568 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinine (8 mg/kg every 8 h for 3 or 5 days)
Number of subjects: 166
Study 8311568 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulphadoxine-pyrimethamine (25-1.25 mg/kg, in one dose)
Number of subjects: 166
Study 8311568 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 166
Study 3752341 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistive training with muscle stimulation (last 12 sessions of 24 total sessions)
Number of subjects: 27
Study 3752341 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistive training alone (24 sessions)
Number of subjects: 27
Study 3752341 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 27
Study 31329828 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced nutritional support pathway including extended preoperative nutritional support and one month home enteral nutrition (HEN)
Number of subjects: 50
Study 31329828 — intervention group
Group type: COMPARATOR
Intervention: Conventional nutritional support
Number of subjects: 50
Study 29521887 — intervention group
Group type: EXPERIMENTAL
Intervention: Team-Based Learning (TBL), 6 hours (2 hours weekly for 3 weeks)
Number of subjects: 183
Study 29521887 — intervention group
Group type: COMPARATOR
Intervention: Lecture-style classes, 6 hours (2 hours weekly for 3 weeks)
Number of subjects: 183
Study 29521887 — intervention group
Group type: EXPERIMENTAL
Intervention: Team-Based Learning (TBL)
Number of subjects: 183
Study 26849477 — intervention group
Group type: COMPARATOR
Intervention: Soccer exercise
Number of subjects: 107
Study 26849477 — intervention group
Group type: COMPARATOR
Intervention: Zumba exercise
Number of subjects: 107
Study 26849477 — intervention group
Group type: EXPERIMENTAL
Intervention: Control group
Number of subjects: 107
Study 24676848 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-magnitude high-frequency vibration (LMHFV) - 20 min daily, 35 Hz, 0.3 g, 5 days/week for 18 months
Number of subjects: 710
Study 24676848 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 710
Study 24676848 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-magnitude high-frequency vibration (LMHFV)
Number of subjects: 710
Study 22172728 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan
Number of subjects: 0
Study 22172728 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine
Number of subjects: 0
Study 22172728 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 20671901 — intervention group
Group type: EXPERIMENTAL
Intervention: Training of primary health care staff in mental health integration
Number of subjects: 3000
Study 20671901 — intervention group
Group type: EXPERIMENTAL
Intervention: Training of supervisors (psychiatrists, psychiatric nurses, district public health nurses)
Number of subjects: 3000
Study 18386103 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-specific reminders mailed to physicians
Number of subjects: 717
Study 18386103 — intervention group
Group type: COMPARATOR
Intervention: No reminders to physicians (Control)
Number of subjects: 717
Study 16060962 — intervention group
Group type: EXPERIMENTAL
Intervention: losartan 50 mg
Number of subjects: 40
Study 16060962 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 40
Study 11949911 — intervention group
Group type: EXPERIMENTAL
Intervention: Minnesota Family Investment Program (MFIP)
Number of subjects: 879
Study 10087643 — intervention group
Group type: EXPERIMENTAL
Intervention: Disgust mood induction
Number of subjects: 0
Study 10087643 — intervention group
Group type: COMPARATOR
Intervention: Control group (nonphobic participants)
Number of subjects: 0
Study 7583899 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine-bupivacaine-morphine
Number of subjects: 0
Study 7583899 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine-morphine
Number of subjects: 0
Study 2182976 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitriol (1,25‐(OH)2D3)
Number of subjects: 27
Study 2182976 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 7025769 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefamandole (Group II)
Number of subjects: 136
Study 7025769 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefamandole plus carbenicillin (Group III)
Number of subjects: 136
Study 7025769 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Group I)
Number of subjects: 136
Study 31512448 — intervention group
Group type: EXPERIMENTAL
Intervention: Isokinetic group
Number of subjects: 40
Study 31512448 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study 27573416 — intervention group
Group type: EXPERIMENTAL
Intervention: Make a Move intervention
Number of subjects: 0
Study 26578668 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training
Number of subjects: 2279
Study 26578668 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 2279
Study 23833960 — intervention group
Group type: EXPERIMENTAL
Intervention: Alzheimer's disease patients (AD group)
Number of subjects: 36
Study 23833960 — intervention group
Group type: COMPARATOR
Intervention: Control group (patients without AD)
Number of subjects: 36
Study 23007280 — intervention group
Group type: EXPERIMENTAL
Intervention: Transjugular intrahepatic portosystemic shunt (TIPS)
Number of subjects: 154
Study 23007280 — intervention group
Group type: COMPARATOR
Intervention: Emergency portacaval shunt (EPCS)
Number of subjects: 154
Study 19181448 — intervention group
Group type: EXPERIMENTAL
Intervention: Schedule II opioids (strong opioids)
Number of subjects: 0
Study 19181448 — intervention group
Group type: EXPERIMENTAL
Intervention: Any type of opioid prescriptions for >or=90 days
Number of subjects: 0
Study 19181448 — intervention group
Group type: EXPERIMENTAL
Intervention: Schedule II opioids
Number of subjects: 0
Study 19181448 — intervention group
Group type: COMPARATOR
Intervention: No opioid prescriptions
Number of subjects: 0
Study 17188618 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral steroids and oral cyclophosphamide (CYC) (maximum total dose 150 mg/kg) followed by oral methotrexate (MTX) (12.5 mg/m(2)/week) for maintenance.
Number of subjects: 6
Study 17188618 — intervention group
Group type: COMPARATOR
Intervention: Oral steroids and methotrexate (MTX) (12.5 mg/m(2)/week).
Number of subjects: 6
Study 15534533 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoroscopy‐based computer navigation system
Number of subjects: 50
Study 15534533 — intervention group
Group type: COMPARATOR
Intervention: Conventional instruments
Number of subjects: 50
Study 11331315 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose interferon alfa-2b (HDI) for 1 year
Number of subjects: 880
Study 11331315 — intervention group
Group type: COMPARATOR
Intervention: GM2 conjugated to keyhole limpet hemocyanin and administered with QS-21 (GMK) for 96 weeks
Number of subjects: 880
Study 9205817 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of zolmitriptan (3.5 mg)
Number of subjects: 12
Study 9205817 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral tablet of zolmitriptan (10 mg)
Number of subjects: 12
Study 9205817 — intervention group
Group type: EXPERIMENTAL
Intervention: Administration of 25 mg [14C]-zolmitriptan capsule
Number of subjects: 12
Study 9205817 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous dosing of zolmitriptan
Number of subjects: 12
Study 8434963 — intervention group
Group type: EXPERIMENTAL
Intervention: NK 622 (toremifene citrate) 40 mg/day
Number of subjects: 57
Study 8434963 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen (TAM) 20 mg/day
Number of subjects: 57
Study 3660148 — intervention group
Group type: EXPERIMENTAL
Intervention: Neonatalyte (Sabax)
Number of subjects: 0
Study 3660148 — intervention group
Group type: COMPARATOR
Intervention: Control solution
Number of subjects: 0
Study 30992334 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose subcutaneous heparin (LDSH)
Number of subjects: 2416
Study 29402816 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant rTMS (5 times a week for 30 min)
Number of subjects: 12
Study 29402816 — intervention group
Group type: COMPARATOR
Intervention: Sham condition (5 times a week for 30 min)
Number of subjects: 12
Study 26457101 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training (Respivol) for 8 weeks (15 min/day for 6 days/week)
Number of subjects: 30
Study 26457101 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 30
Study 26457101 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training (Respivol)
Number of subjects: 30
Study 23410986 — intervention group
Group type: EXPERIMENTAL
Intervention: VES‐ODT (orally disintegrating tablet)
Number of subjects: 30
Study 23410986 — intervention group
Group type: COMPARATOR
Intervention: VES‐CT (conventional tablet)
Number of subjects: 30
Study 20716398 — intervention group
Group type: EXPERIMENTAL
Intervention: Nortriptyline
Number of subjects: 630
Study 20716398 — intervention group
Group type: COMPARATOR
Intervention: Escitalopram
Number of subjects: 630
Study 19846545 — intervention group
Group type: EXPERIMENTAL
Intervention: High-normal arterial pH (7.43-7.45)
Number of subjects: 8
Study 19846545 — intervention group
Group type: COMPARATOR
Intervention: Low-normal arterial pH (7.36-7.38)
Number of subjects: 8
Study 17075402 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative debridement
Number of subjects: 60
Study 17075402 — intervention group
Group type: COMPARATOR
Intervention: Control (saline irrigation only)
Number of subjects: 60
Study 14998427 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-day training program on rational pharmacotherapy
Number of subjects: 25
Study 14998427 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 25
Study 11463766 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin-(1-7) infusion (10(-10), 10(-9), and 10(-8) mol/min for 5 minutes)
Number of subjects: 16
Study 11463766 — intervention group
Group type: COMPARATOR
Intervention: N(G)-monomethyl-L-arginine (nitric oxide synthesis inhibitor)
Number of subjects: 16
Study 9990418 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapalene 0.1% gel
Number of subjects: 105
Study 9990418 — intervention group
Group type: COMPARATOR
Intervention: Tretinoin 0.025% gel
Number of subjects: 105
Study 8065201 — intervention group
Group type: EXPERIMENTAL
Intervention: Back up pressure ventilation with facial mask (BUPM)
Number of subjects: 18
Study 8065201 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (CONV)
Number of subjects: 18
Study 2567745 — intervention group
Group type: EXPERIMENTAL
Intervention: Performance-based treatment for some phobic areas
Number of subjects: 27
Study 4909766 — intervention group
Group type: EXPERIMENTAL
Intervention: High oral doses of marihuana extract (1 (‐)‐Delta(1)‐tetrahydrocannabinol)
Number of subjects: 0
Study 31060845 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified 2-rescuer CPR technique with a 2-handed mask seal
Number of subjects: 94
Study 31060845 — intervention group
Group type: COMPARATOR
Intervention: Standard 2-rescuer CPR
Number of subjects: 94
Study 28025037 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled tobramycin with azithromycin
Number of subjects: 0
Study 28025037 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled aztreonam after tobramycin
Number of subjects: 0
Study 28025037 — intervention group
Group type: COMPARATOR
Intervention: Inhaled tobramycin without azithromycin
Number of subjects: 0
Study 26234407 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactococcus lactis ssp. lactis JCM5805 yogurt
Number of subjects: 213
Study 26234407 — intervention group
Group type: COMPARATOR
Intervention: Placebo beverage
Number of subjects: 213
Study 22646754 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group with implemented delirium guidelines
Number of subjects: 206
Study 22646754 — intervention group
Group type: COMPARATOR
Intervention: Control group without implemented delirium guidelines
Number of subjects: 206
Study 22646754 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 206
Study 22646754 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 206
Study 21248785 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine/valsartan/hydrochlorothiazide (10/320/25 mg)
Number of subjects: 2271
Study 21248785 — intervention group
Group type: COMPARATOR
Intervention: Dual therapies (valsartan/hydrochlorothiazide, amlodipine/valsartan, amlodipine/hydrochlorothiazide)
Number of subjects: 2271
Study 17971827 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron and folic acid (30 mg) with micronutrients
Number of subjects: 250
Study 17971827 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron and folic acid (30 mg) without micronutrients
Number of subjects: 250
Study 17971827 — intervention group
Group type: COMPARATOR
Intervention: Placebo control (PlbCON)
Number of subjects: 250
Study 17380489 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 cm2 rivastigmine patch
Number of subjects: 1195
Study 17380489 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 cm2 rivastigmine patch
Number of subjects: 1195
Study 17380489 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 mg/day rivastigmine capsules
Number of subjects: 1195
Study 17380489 — intervention group
Group type: EXPERIMENTAL
Intervention: All patch sizes (5, 10, 15, and 20 cm2)
Number of subjects: 1195
Study 15126761 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone-anchored hearing aid fitting
Number of subjects: 94
Study 11161897 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective decontamination of digestive tract (SDD)
Number of subjects: 61
Study 11161897 — intervention group
Group type: EXPERIMENTAL
Intervention: No intervention (non-SDD unit)
Number of subjects: 61
Study 11161897 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 61
Study 9562504 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 60
Study 9562504 — intervention group
Group type: COMPARATOR
Intervention: Adjustment with risk factors (hypertension, myocardial infarction, factor VIIc, factor VIIIc, cholesterol, HDL cholesterol, smoking, diabetes mellitus)
Number of subjects: 60
Study 9562504 — intervention group
Group type: COMPARATOR
Intervention: Adjustment with fibrinogen and indicators of carotid atherosclerosis (intima-media wall thickness, plaques)
Number of subjects: 60
Study 9562504 — intervention group
Group type: COMPARATOR
Intervention: Correction with local ratings of cortical atrophy
Number of subjects: 60
Study 7836964 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpromazine (CHLP, 50 mg, i.m.)
Number of subjects: 41
Study 7836964 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep deprivation (SD)
Number of subjects: 41